I'm still in. Think the surest bet we have going for us is the SCM case. $30M would do wonders for this stock and it has nothing to do with validity in the patents.....the case is all about a contract breach that SCM is in violation of. Add that into a Celgene payment and delayed MMR PRo payments and i really think this could be a very successful year regardless of what else happens.
Not going anywhere any time soon, and I look forward to how the WebMD situation play's out for MMR and the shareholders.
It's interesting that Mr. Lorsch is headed to Washington, New Jersey, and New York this week, and I would expect some sort of results soon from this trip.
The most interesting part is that Ward, will be tagging along, so this could get very interesting sooner rather than later.
Market Data 
Markets 
AI
